Lab's Non-Coverage Notice Deters Medicare Patients
However, the version of the form Quest is distributing does not inform patients that Medicare covers the test every three months. The form includes this language that Medicare officials say is problematic:
- "Medicare does not pay for these tests for your condition."
- "Medicare does not pay for these tests as often as this (denied as too frequent)."
- "Medicare does not pay for experimental or research use tests."
- The "estimated cost" is $66.
This form "does not comply with the standards for valid ABN issuance," Medicare's Jennifer Smith, director of the Division of Appeals Policy and Evelyn Blaemire, Senior Health Insurance Specialist, said in an e-mail response to HealthLeaders Media.
The rule specifies that the provider "must clearly indicate on the ABN which portions of the pre-printed information are applicable."
The Quest form has been in place for about two months in a region covering eight Southern California counties, or about 21 million people. Of those, about 13% are Medicare beneficiaries. More than 20% of Medicare beneficiaries are estimated to have diabetes, or about 554,000 people in this area who should receive quarterly A1c tests. Quest is one of two major labs serving this population. The other, LabCorps, does not use these forms, Speckart says.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- Ebola: Health Officials Try to Quell Front Line Fears
- How Telehealth Pays Off for Providers, Patients
- Reducing Readmissions Starts with Better Collaboration
- Defensive Medicine Still Prevalent Despite Tort Reform
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- Ebola: A New Normal in Dallas
- Partners HealthCare M&A Deal Under Scrutiny
- How Educated Nurses Save Money
- How Top-Ranked MA Plans Earn Their Stars